Free Trial
TSE:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

BELLUS Health logo

About BELLUS Health Stock (TSE:BLU)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
28,666 shs
Average Volume
59,471 shs
Market Capitalization
C$2.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More Headlines

BLU Stock Analysis - Frequently Asked Questions

Shares of BLU stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Advanced Micro Devices (AMD), Algonquin Power & Utilities (AQN), BCE (BCE), Canadian Natural Resources (CNQ) and Nutrien (NTR).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:BLU
CIK
N/A
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-86,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$16,000.00
Price / Cash Flow
4.67
Book Value
C$2.91 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$2.47 billion
Optionable
Not Optionable
Beta
-0.28
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (TSE:BLU) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners